To do that, we collected astrocyte conditioned medium (ACM) from astrocytes cultured for 14 days and added Tocilizumab (a humanized monoclonal antibody against IL-6 receptor (IL-6R), FDA-approved, clinically used in rheumatoid arthritis) to L2-PD–ACM and treated hiPSC-derived CTL or L2-PD neurons for 1 week (Figure 3A). This evidence concerns the gene IL6R and rheumatoid arthritis.